Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients. [electronic resource]
Producer: 20190520Description: 70-78 p. digitalISSN:- 1600-0609
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Bortezomib -- administration & dosage
- Clarithromycin -- administration & dosage
- Clinical Protocols
- Cyclophosphamide -- administration & dosage
- Denmark -- epidemiology
- Dexamethasone -- administration & dosage
- Female
- Humans
- Induction Chemotherapy
- Male
- Middle Aged
- Multiple Myeloma -- diagnosis
- Neoplasm Staging
- Quality of Life
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.